论文部分内容阅读
目的探讨拜阿司匹林联合阿托伐他汀治疗脑血管病的临床效果。方法选取洛阳市第六人民医院2014年1月—2015年1月收治的60例脑血管病患者,根据入院先后顺序分为对照组与观察组,各30例。两组患者均给予脑血管病常规治疗,对照组加用拜阿司匹林治疗,观察组在对照组基础上加用阿托伐他汀治疗,比较两组患者治疗前和治疗1年后血清氧化低密度脂蛋白、高敏C-反应蛋白水平、颈动脉中膜厚度及不良反应发生率。结果治疗前两组患者血清氧化低密度脂蛋白、高敏C-反应蛋白水平及颈动脉中膜厚度比较,差异无统计学意义(P>0.05);治疗后观察组患者血清氧化低密度脂蛋白、高敏C-反应蛋白水平及颈动脉中膜厚度低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿托伐他汀联合拜阿司匹林治疗脑血管病的临床效果确切,且安全性高。
Objective To investigate the clinical effect of aspirin combined with atorvastatin in the treatment of cerebrovascular disease. Methods Sixty patients with cerebrovascular disease who were admitted to Luoyang Sixth People’s Hospital from January 2014 to January 2015 were selected and divided into control group and observation group according to the order of admission. Two groups of patients were given conventional treatment of cerebrovascular disease, the control group plus aspirin treatment, the observation group on the basis of the control group plus atorvastatin treatment, two groups before treatment and after treatment of serum oxidized low-density lipids Protein, high-sensitivity C-reactive protein, carotid intima-media thickness and the incidence of adverse reactions. Results There was no significant difference in serum oxidized low density lipoprotein, high-sensitivity C-reactive protein and carotid artery media thickness between the two groups before treatment (P> 0.05). After treatment, serum oxidized low density lipoprotein, High-sensitivity C-reactive protein and carotid intima-media thickness were lower than the control group, the difference was statistically significant (P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Atorvastatin combined with aspirin in the treatment of cerebrovascular disease has clinical effect and high safety.